Molecule-4

Molecule-4 is a synthetic small molecule hybrid designed as a histone deacetylase (HDAC) inhibitor. Developed by researchers at Mansoura University, it was engineered to address the pharmacokinetic limitations and systemic toxicities (such as bone marrow suppression and cardiotoxicity) associated with traditional hydroxamate-based HDAC inhibitors like vorinostat. The molecule's structure features a natural antioxidant scaffold, specifically derived from caffeic acid, conjugated to an ortho-aminoanilide moiety that functions as a zinc-binding group (ZBG). This hybridization strategy is intended to combine the epigenetic modulating effects of HDAC inhibition with the cytoprotective properties of natural antioxidants. In preclinical studies, Molecule-4 has demonstrated potent antineoplastic activity against various cancer cell lines, including breast and colon cancer, by inducing cell cycle arrest and apoptosis. It shows a preference for Class I HDAC isoforms and exhibits improved metabolic stability compared to first-generation inhibitors.

Other names

Molecule-4Molecule4Molecule 4